Exploring Potential Phytochemicals for Myasthenia Gravis Treatment: A Molecular Docking and ADME Analysis Approach

Year : 2024 | Volume : 02 | Issue : 02 | Page : 1 13
    By

    Neha Subhash Nilawad,

  1. Student, Departmentof Bioinformatics, Institute of Bioscience and Technology, MGM University, Chhatrapati Sambhaji Nagar, Maharashtra, India

Abstract

Objective: Muscle feebleness and exhaustion derived from a disruption in neuromuscular transference are hallmarks of the crippling autoimmune disease myasthenia gravis (MG). The drawbacks of the current MG therapy options are frequently partial efficacy and adverse effects. To investigate the potential of phytochemicals in MG control, in this work we integrated molecular docking with ADME (absorption, distribution, metabolism, and excretion) analysis using a computer method. We identified molecules exhibiting favorable interactions with key molecular targets implicated in MG pathophysiology, such as muscle-specific kinase (MuSK), nicotinic acetylcholine receptors (nAChRs), and acetylcholinesterase (AChE). Explore the natural substances called phytochemicals that are derived from plants and may have therapeutic uses in treating a variety of ailments, including autoimmune disorders. This has become more and more popular in the past few years. Methods: Theoretical Methodology: This study aims to explore the potential of phytochemicals from the Cassia fistula medicinal plant for the treatment of Myasthenia gravis (MG) through a multi-step computational approach. Firstly, the top five phytochemicals from Cassia fistula will be selected based on a literature review and computational screening. These compounds will then undergo molecular docking onto the active site of the muscle-specific kinase (MuSK) protein (PDB ID: 1LUF) using PyRx software to predict their binding affinities and interactions. Following this, ADME (absorption, distribution, metabolism, and excretion) analysis will be conducted to evaluate the pharmacokinetic properties of the docked compounds, including bioavailability and toxicity. To identify possible lead compounds for additional experimental validation, Biovia software will be used to visualize protein-ligand interactions. This integrated approach holds promise for the discovery of novel phytochemical-based therapeutics for MG treatment. Result: Molecular docking investigations indicated that Rhein, chrysophanic acid, aromadendrin, aloe emodin, and anthraquinone were in the ligands with the lowest binding affinities to the targeted proteins. Conclusion: In conclusion, we have effectively discovered phytochemicals with promise for treating Myasthenia gravis (MG) by our molecular docking and ADME analysis technique utilizing Biovia and PyRx. Using computational screening, we found phytochemicals with good pharmacokinetic characteristics and a substantial binding affinity to MG-related target proteins. These results demonstrate the possibility of using natural substances as MG treatment alternatives. To determine these compounds’ safety and efficacy and to prepare the way for the creation of novel MG therapies based on phytochemicals, more experimental validation of these compounds is necessary.

Keywords: Myasthenia gravis, phytochemicals, molecular docking, adme analysis, neuromuscular transmission, precision medicine

[This article belongs to International Journal of Molecular Biotechnological Research ]

How to cite this article:
Neha Subhash Nilawad. Exploring Potential Phytochemicals for Myasthenia Gravis Treatment: A Molecular Docking and ADME Analysis Approach. International Journal of Molecular Biotechnological Research. 2024; 02(02):1-13.
How to cite this URL:
Neha Subhash Nilawad. Exploring Potential Phytochemicals for Myasthenia Gravis Treatment: A Molecular Docking and ADME Analysis Approach. International Journal of Molecular Biotechnological Research. 2024; 02(02):1-13. Available from: https://journals.stmjournals.com/ijmbr/article=2024/view=183799


Browse Figures

References

1. Thanvi BR, Lo TCN. Update on myasthenia gravis. Postgrad Med J. 2004;80(950):690–700. doi:10.1136/pgmj.2004.018903.
2. Eldaabossi S, Alrashdan M, Aljanobi G, Warsha N, Elhassan SA, Mahdi W, et al. A rare association: Obesity hypoventilation syndrome with myasthenia gravis and systemic lupus erythematosus, case report. Respir Med Case Rep. 2023;44:101848. doi:10.1016/j.rmcr.2023.101848.
3. Cao M, Koneczny I, Vincent A. Myasthenia gravis with antibodies against muscle specific kinase: an update on clinical features, pathophysiology and treatment. Front Mol Neurosci . 2020;13:159. doi:10.3389/fnmol.2020.00159.
4. Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune Dis. 2012;2012(1):874680. doi:10.1155/2012/874680.
5. Marsteller HB. The first American case of myasthenia gravis. Arch Neurol. 1988;45(2):185–187. doi:10.1001/archneur.1988.00520260073024.
6. Somnier FE. Myasthenia gravis-occurrence, failure in neuromuscular transmission, clinical implementation of anti-AChR antibodies, and therapeutic progress. Dan Med Bull. 1996;43(1):1–10.
7. Evoli A. Acquired myasthenia gravis in childhood. Curr Opin Neurol. 2010;23(5):536–540. doi:10.1097/WCO.0b013e32833c32af.
8. Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, et al. Response to therapy in myasthenia gravis with anti‐MuSK antibodies. Ann N Y Acad Sci. 2008;1132(1):76–83. doi:10.1196/annals.1405.012.
9. Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Neurol. 2000;55(1):16–23. doi:10.1212/WNL.55.1.1.
10. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893–902. doi:10.1111/j.1468-1331.2010.03019.x.
11. Elovaara I, Apostolski S, Van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15(9):893–908. doi:10.1111/j.1468-1331.2008.02246.x.
12. Leite MI, Waters P, Vincent A. Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity. 2010;43(5–6):371–379. doi:10.3109/08916930903541208.
13. Matsumoto Y, Matsuo H, Sakuma H, Park IK, Tsukada Y, Kohyama K, et al. CDR3 spectratyping analysis of the TCR repertoire in myasthenia gravis. J Immunol. 2006;176(8):5100–5107. doi:10.4049/jimmunol.176.8.5100.
14. Mohanraj K, Karthikeyan BS, Vivek-Ananth RP, Chand RB, Aparna SR, Mangalapandi P, et al. IMPPAT: A curated database of Indian medicinal plants, phytochemistry and therapeutics. Sci Rep. 2018;8(1):4329. doi:10.1038/s41598-018-22631-z.
15. Saldívar-González FI, Huerta-García CS, Medina-Franco JL. Chemoinformatics-based enumeration of chemical libraries: a tutorial. J Cheminform. 2020;12(1):64. doi:10.1186/s13321-020-00466
16. Chen SC, Chen T. Retrieval of 3D protein structures. International Conference on Image Processing. Rochester, NY, USA. 2002, Sep 22-25. 933–936. IEEE. doi:10.1109/ICIP.2002.1039126.
17. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 2003;31(13):3381–3385. doi:10.1093/nar/gkg520.
18. Adrees S, Imtiaz A, Yaseen A, Irfan Fareed M, Anwar W, Ashraf A, et al. In-silico analysis of potential anticancer drug for NEK7 and PPP1CA proteins overexpressed in pancreatic ductal adenocarcinoma. J Biomol Struct Dyn. 2024;26:1–7. doi:10.1080/07391102.2024.2318484.
19. Ahmad I, Khan H, Serdaroğlu G. Physicochemical properties, drug likeness, ADMET, DFT studies, and in vitro antioxidant activity of oxindole derivatives. Comput Biol Chem. 2023;104:107861. doi:10.1016/j.compbiolchem.2023.107861.
20. Morris GM, Lim-Wilby M. Molecular docking. In: Kukol A, editor. Molecular Modeling of Proteins. Methods Molecular Biology. Totowa, NJ: Humana Press; 2008. 365–382. doi:10.1007/978-1-59745-177-2_19.
21. Dallakyan S, Olson AJ. Small-Molecule Library Screening by Docking with PyRx. In: Hempel J, Williams C, Hong C, editors. Chemical Biology: Methods in Molecular Biology. New York, NY: Humana Press; 2015. 243–250. doi:10.1007/978-1-4939-2269-7_19.
22. Sharma S, Sharma A, Gupta U. Molecular docking studies on the anti-fungal activity of Allium sativum (Garlic) against mucormycosis (black fungus) by BIOVIA discovery studio visualizer 21.1. 0.0. Ann Antivir Antiretrovir. 2021;5(1):28–32. doi:10.17352/aaa.000013.
23. Morris AL, MacArthur MW, Hutchinson EG, Thornton JM. Stereochemical quality of protein structure coordinates. Proteins. 1992;12(4):345–364. doi:10.1002/prot.340120407

Regular Issue Subscription Original Research
Volume 02
Issue 02
Received 07/09/2024
Accepted 28/10/2024
Published 18/11/2024
Publication Time 72 Days
324

Login


My IP

PlumX Metrics